You are here
Pfizer Partners With NIH, Non-Profits and Industry Peers to Speed Validation of Disease Targets
Pfizer is partnering with the National Institute of Health (NIH), along with 9 other biopharmaceutical companies and several non-profit organizations to launch a transformative collaboration aimed at changing the model for identifying and validating biological targets and diagnostics with an aim to speed the development of potential new therapies for patients. The initiative known as Accelerating Medicines Partnership (AMP) was announced at a press conference yesterday in Washington, D.C.
Pfizer's participation in the initiative will focus on hard-to-treat disease areas of Type 2 Diabetes and the autoimmune disease Rheumatoid Arthritis/Lupus. Pfizer's Head of Worldwide Research and Development, Mikael Dolsten who has been involved since the inception of this project and commented, "The AMP rallies key scientific players of the innovation ecosystem in a more unified way to address one of the key challenges to biopharma drug discovery and development."
He added, "This type of novel collaboration will leverage the strengths of the industry, non-profits and the NIH to ensure we expedite translation of scientific knowledge into potential next generation therapies to address urgent patient needs."